The bone void-filling solution enables healthcare professionals to directly administer Zimmer Biomet’s N-Force Blue-bone substitute material (BSM) and CelgenTek’s iN3 Cement directly via a fenestrated screw in a single construct.

CelgenTek Innovations CEO Thomas Russell said: "We are honored to partner with Zimmer Biomet in expanding the reach and influence of our orthobiologic portfolio with the commercial capabilities of an innovation leader in global musculoskeletal healthcare.

"CelgenTek Innovations is positioned at the forefront of clinical innovation in the United States, Europe and Australia, and in partnership with Zimmer Biomet we aim to accelerate our strategies for ongoing growth."

Under the deal, CelgenTek will involve in the design and manufacturing of the N-Force Fixation System and iN3 Cement.

The N-Force Fixation System is an augmented fixation system, which received approval in the US, while iN3 is a pre-mix calcium phosphate cement available in the European Union.

The N-Force system includes fenestrated screws, washers and the N-Force Blue- bone substitute material.

The bone substitute material is injected directly through the fenestrated screw, offering not only fixation, but also serving as the delivery system for filling the void.